Venus Remedies Ltd

Venus Remedies Ltd maintains a strong liquidity position, with a current ratio of 4.53, indicating that the company has more than four times the current assets to cover its current liabilities. The company's liquidity_fpt score is high, supported by INR 489.56 million in cash and equivalents, which provides a buffer against short-term obligations. The debt-to-equity ratio of 0.08 suggests a conservative capital structure, with minimal reliance on long-term debt, which is below the industry median for pharmaceutical firms.

In terms of profitability, Venus Remedies Ltd reported a net income of INR 105.21 million on revenue of INR 1.95 billion, translating to a net margin of 5.39%. The return on equity (ROE) of 2.16% and return on assets (ROA) of 1.68% are below the industry median for pharmaceutical companies, indicating that the company is generating returns at a slower pace relative to its peers. The gross profit margin of 38.48% is in line with the industry, but the operating margin of 6.90% is slightly below the median, suggesting potential inefficiencies in operating costs.

The company's revenue is concentrated in the domestic market, with no significant international operations disclosed. The business is primarily driven by its pharmaceutical products, with no material diversification into other healthcare segments. The lack of geographic diversification may expose the company to regulatory and macroeconomic risks specific to India.

Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or contraction projected in the next fiscal year. The capital expenditure of INR -135.18 million indicates a reduction in investment in physical assets, which may reflect a shift toward cost optimization or a focus on cash preservation. The company's operating cash flow of INR 372.85 million supports its liquidity and provides flexibility for future reinvestment.

The risk assessment indicates a low probability of dilution and no immediate liquidity concerns. The company has not issued new shares recently, and there are no signs of impending equity offerings or convertible debt conversions. The absence of dilution risk is a positive signal for shareholders, as it preserves ownership concentration and EPS growth potential.

Recent filings and transcripts do not highlight any material events or strategic shifts. The company's price targets from analysts are uniformly set at INR 326.00, suggesting a consensus on its fair valuation. There are no recent earnings surprises or regulatory actions that would significantly alter the company's trajectory.

Operating income surged 77.2% year-over-year to INR 514.7 million, demonstrating significant operational leverage and margin expansion capabilities.

The company maintains a robust balance sheet with long-term debt reduced to just INR 16.9 million, minimizing financial risk.

Operating and net margins exceed pharmaceutical cohort medians, indicating superior profitability relative to 821 and 828 peers respectively.

Net income grew at a 14.3% CAGR over four years, outpacing the 3.9% revenue growth rate.

Cash conversion ratio of 3.54 is best-in-class compared to the cohort median of 0.95, highlighting efficient cash generation.

Revenue growth has slowed significantly, with a four-year CAGR of only 3.9%, indicating limited top-line expansion potential.

Revenue INR 6.01B, +8,3% YoY; Operating income +18,6% YoY.

• ▍Revenue INR 6.01B, +8,3% YoY
• ▍Operating income +18,6% YoY
• ▍Net income +7,2% YoY
• ▍Free cash flow −18,9% YoY
• ▍Net margin 4.7%

Revenue INR 5.56B, −7,2% YoY; Operating income −2,2% YoY.

• ▍Revenue INR 5.56B, −7,2% YoY
• ▍Operating income −2,2% YoY
• ▍Net income −34,8% YoY
• ▍Free cash flow −15,7% YoY
• ▍Net margin 4.8%